DropGenie has developed a novel microfluidic platform to enable genome-wide arrayed CRISPR screening in primary cells, addressing challenges in precision medicine. This platform minimizes the need for a large number of cells per edit, reducing cellular input requirements from millions to thousands, while maintaining high efficiency and without compromising viability. It can deliver various payloads, such as mRNA, RNP, and DNA, efficiently without affecting cell function. The platform is versatile, working effectively with different primary cell types, including immune cell subsets, stem cells, and other complex cellular systems. The editing cartridge integration with automation enables the execution of thousands of edits per day without human intervention, making drug discovery more cost-effective and efficient at the single-donor level. We present here a workflow with Beckman Coulter Life Sciences to showcase the use of the Echo 655T acoustic liquid handler as well as the Biomek i7 hybrid liquid handler with the DropGenie platform to deliver on the promise of low-volume, high-throughput discovery.
.png)
